According to Future Market Insights (FMI) analysis in a recent market survey, the global alcoholic hepatitis treatment market was valued at USD 2.6 Billion in 2022 and is expected to reach USD 5.3 Billion by 2033.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 2.6 Billion |
| Market Value 2023 | USD 2.8 Billion |
| Market Value 2033 | USD 5.3 Billion |
| CAGR 2023 to 2033 | 6.5% |
| Share of Top 5 Countries | 70.0% |
| Key Players | F. Hoffmann-La Roche Ltd (Genentech; Inc); Teva Pharmaceuticals; Pfizer; Alkermes; Inc; Viatris Inc; Merck KGaA; Sun Pharmaceutical Industries Ltd; Hikma Pharmaceuticals PLC; H. Lundbeck A/S; Mallinckrodt; Glenmark Pharmaceuticals USA Inc; Torrent Pharmaceuticals Ltd; Wellona Pharma |
Stem cell therapy is emerging as a promising treatment for alcoholic hepatitis. This therapy involves using stem cells to improve liver function and regenerate damaged liver tissue. As research in this area continues to grow, stem cell therapy is expected to become a more commonly used treatment option. There is a growing focus on patient-centric care in the market. Healthcare providers are increasingly tailoring treatment plans to meet the specific needs and preferences of individual patients, taking into account factors such as age, gender, lifestyle, and medical history.
Overall, the market is evolving rapidly, with new technologies, therapies, and treatment approaches emerging all the time. The industry is becoming increasingly patient-centric, with a greater emphasis on personalized treatment plans that offer the best possible outcomes for individual patients.
Explore FMI!
Book a free demo
Sales of the market grew at a CAGR of 3.8% between 2012 and 2022. The alcoholic hepatitis treatment market contributes 15.0% revenue share to the global liver diseases treatment market which is USD 17.5 Billion in 2022.
The market has been growing steadily in recent years and is expected to continue to do so in the coming years. The market is being driven by several factors, including an increased prevalence of liver diseases caused by alcohol consumption, a growing demand for effective treatments, and advancements in medical technology.
The primary driver of the market is the increasing prevalence of liver diseases caused by alcohol consumption. As more people consume alcohol and in higher quantities, the incidence of liver diseases such as alcoholic hepatitis has been on the rise.
Governments are providing funding for research into the causes, prevention, and treatment of liver diseases caused by alcohol consumption. This funding is driving the development of new therapies and technologies that are more effective in treating alcoholic hepatitis. Governments are implementing awareness campaigns aimed at educating the public about the risks associated with excessive alcohol consumption and the importance of early diagnosis and treatment. These campaigns are increasing public awareness of the disease and driving demand for effective treatments.
Therefore, favorable government initiatives are playing an important role in driving the growth of the market by increasing public awareness of the disease, improving access to healthcare, and supporting the development of new therapies and technologies.
Considering this, FMI expects the global market is projected to expand at a CAGR of 6.5% through the forecasted years.
Advancements in technology are expected to create opportunities for the market. There have been significant advancements in the field of liver disease treatment in recent years, including the development of new drugs, diagnostic tools, and surgical techniques, which have the potential to improve outcomes for patients with alcoholic hepatitis.
Diagnostic tools, such as imaging techniques and blood tests, are also being developed to help healthcare professionals diagnose alcoholic hepatitis more accurately and at an earlier stage. This can help improve patient outcomes by allowing for earlier treatment interventions.
Surgical techniques, such as liver transplantation, can also be used to treat severe cases of alcoholic hepatitis. Advances in surgical techniques and improved patient selection criteria have led to better outcomes for patients undergoing liver transplantation.
Overall, the advancements in technology in the field of liver disease treatment are expected to provide new and improved treatment options for patients with alcoholic hepatitis, which could drive the growth of the market.
Several factors could potentially restrain the market’s growth. Some of these factors include:
The cost of treatment for alcoholic hepatitis can be high, particularly for advanced cases that require hospitalization or liver transplantation. This can limit access to treatment for some patients, particularly in low- and middle-income countries. Some of the medications used to treat alcoholic hepatitis can have significant side effects, such as an increased risk of infection or bleeding. This can limit their use in certain patients, particularly those with pre-existing health conditions.
While there are some treatments available for alcoholic hepatitis, their effectiveness can be limited in certain patients. For example, some patients may not respond well to corticosteroids, which are commonly used to treat severe cases of the disease. The regulatory approval process for new drugs and treatments can be lengthy and complex, which can limit the availability of new and innovative treatments for alcoholic hepatitis.
Overall, while there are significant opportunities for growth in the market, these factors could potentially limit the market's growth and adoption of treatments in certain patient populations.
The USA market contributes a market share of 94.0% to the North American market in 2022 and is expected to register to grow at a high pace during the forecast period.
The USA has a relatively high prevalence of alcoholic hepatitis, which is largely driven by the high rates of alcohol consumption in the country. This has created a large patient population that requires treatment, which has in turn fueled the growth of the market in the USA
The USA has a favorable reimbursement environment for medical treatments, which has encouraged healthcare providers to offer treatments for alcoholic hepatitis and has facilitated patient access to these treatments.
These factors have contributed to making the USA the dominating country in the market.
Germany dominated the European market for alcoholic hepatitis treatment and accounted for around 8.1% of the global market share in 2022.
There is a growing demand in Germany for minimally invasive procedures for the treatment of liver diseases, including alcoholic hepatitis. This has led to the development and adoption of new procedures, such as transjugular intrahepatic portosystemic shunt (TIPS) and percutaneous ethanol injection (PEI), which are less invasive than traditional surgical treatments.
This has created a large patient population to adopt advanced treatment, which has in turn fueled the growth of the market in Germany.
China is projected to be the most attractive market in alcoholic hepatitis treatment in East Asia with a market share of 77.9% in 2022.
The market in China is projected to expand significantly in the coming years due to several factors.
There is growing awareness in China of the health risks associated with alcohol consumption and liver disease. This has led to increased screening and diagnosis of liver disease, which has in turn fueled the demand for treatments for alcoholic hepatitis.
Another factor contributing to the market’s growth in China is rapidly expanding and modernizing its healthcare infrastructure in recent years, which has increased access to healthcare services for its population. This infrastructure supports the development and adoption of new treatments and technologies for alcoholic hepatitis.
The drug treatment segment held about 88.3% of the global market by the end of 2022.
Drug treatments have become the leading option for treating alcoholic hepatitis in the market because they have been shown to be effective in reducing inflammation and improving liver function. These drugs work by targeting specific pathways involved in the development of alcoholic hepatitis, such as reducing the production of cytokines and other inflammatory mediators.
Overall, drug treatment has proven for better outcomes for patients with this condition and thereby, driving the alcoholic hepatitis treatment market.
The oral route is leading in the market with a market share of 78.2% in 2022 because it offers several advantages over other routes of administration, such as intravenous (IV) or intramuscular (IM) injections.
The oral route of administration is the most common and convenient way to deliver drugs to patients with alcoholic hepatitis. Oral medications are taken by mouth and absorbed through the digestive system, which allows for the drugs to be distributed throughout the body and reach the liver where they are needed.
The institutional sales segment accounted for a revenue share of 55.9% in the global market at the end of 2022.
In the alcoholic hepatitis treatment market, institutional sales have become a leading strategy for pharmaceutical companies to distribute their products to healthcare providers.
Institutional sales have become a leading strategy in the market because they allow pharmaceutical companies to target healthcare providers, offer convenience, sell in large volumes, and collaborate with healthcare institutions.
Key manufacturers in the alcoholic hepatitis treatment market employ a range of strategies to gain a competitive edge and increase their market share. These strategies include developing new and innovative drugs, acquisitions and expansions, strategic collaborations, pricing strategies, and regulatory compliance.
For instance:
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the alcoholic hepatitis treatment market space, which are available in the full report
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2012 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, United Kingdom, France, Italy, Spain, Russia, BENELUX, Nordic Countries, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, South Africa, North Africa, and GCC Countries |
| Key Segments Covered | Treatment, Route of Administration, Distribution Channel, and Region |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd (Genentech, Inc); Teva Pharmaceuticals; Pfizer; Alkermes, Inc; Viatris Inc; Merck KGaA; Sun Pharmaceutical Industries Ltd; Hikma Pharmaceuticals PLC; H. Lundbeck A/S; Mallinckrodt; Glenmark Pharmaceuticals USA. Inc; Torrent Pharmaceuticals Ltd; Wellona Pharma |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global market is valued at around USD 2.6 Billion in 2022.
The global market estimate for 2023 is around USD 2.8 Billion.
The global market is expected to reach USD 5.3 Billion by the end of 2033, with sales revenue expected to be 6.5% CAGR through 2033.
North America dominated the global market in 2022 and the USA is the leading contributor in the North American region with a 94.0% value share in 2022.
Ongoing clinical trials for better medications for alcoholic liver diseases, the upsurge of stem cell therapy, and improving healthcare infrastructure are a few opportunities for the market players to grow.
The drug treatment segment dominated the global market in 2022 with 88.3% revenue share 2022 and is expected to lead in 2023 as well.
The USA, Germany, China, the United Kingdom, and India are the top countries that are driving the demand for alcoholic hepatitis treatment globally.
From 2012 to 2022, the market for alcoholic hepatitis treatment expanded at a rate of 3.8%.
F. Hoffmann-La Roche Ltd (Genentech, Inc), Teva Pharmaceuticals, Pfizer, and Alkermes, Inc. are the key players within the global market.
Screening to reduce ALD-related morbidity and mortality, Omnichannel distribution, optimal health coverage, and agile business models through smart facilities are a few key trends in the global market.
The market is valued at USD 2.8 billion in 2023.
Pfizer, Alkermes, Inc, Viatris Inc are key market players.
The market is forecast to register a CAGR of 6.5% through 2033.
The market is estimated to reach USD 5.3 billion by 2033.
From 2018 to 2022, the market recorded a 3.8% CAGR.
Home Respiratory Therapy Market – Growth & Forecast 2025 to 2035
Veterinary Auto-Immune Therapeutics Market Growth - Trends & Forecast 2025 to 2035
Radial Compression Devices Market Growth - Trends & Forecast 2025 to 2035
Digital Telepathology Market is segmented by Application and End User from 2025 to 2035
Suture Anchor Devices Market Is Segmented by Product Type, Material Type, Tying and End User from 2025 to 2035
Home Infusion Therapy Devices Market - Growth & Forecast 2025 to 2035
Alcoholic Hepatitis Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
